---
schema_version: "secwatch.filing_event.v1"
accession: "0001551152-24-000007"
form_type: "8-K"
ticker: "ABBV"
cik: "0001551152"
company_name: "AbbVie Inc."
filed_at: "2024-02-02T23:59:59+00:00"
generated_at: "2026-06-06T09:54:37.255564+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# AbbVie Q4 adj. EPS $2.79, revenue $14.3B; FY2024 adj. EPS guidance $11.05-$11.25

## Summary
- Full-year 2023 GAAP EPS $2.72 (-59%); adjusted EPS $11.11 (-19.3%); revenue $54.3B (-6.4%).
- Q4 2023 GAAP EPS $0.46 (-66.7%); adjusted EPS $2.79 (-22.5%); revenue $14.3B (-5.4%).
- Humira Q4 revenue $3.3B (-40.8% on biosimilar competition); Skyrizi up 51.9%; Rinvoq up 62.9%.
- Announced ImmunoGen acquisition (~$10.1B equity) and Cerevel (~$8.7B); expected close mid-2024.
- FY2024 adj. EPS guidance $11.05-$11.25 includes $0.32 dilution from pending deals; long-term CAGR reaffirmed.

## SEC filing metadata
- accession: 0001551152-24-000007
- form_type: 8-K
- ticker: ABBV
- cik: 0001551152
- company_name: AbbVie Inc.
- filed_at: 2024-02-02T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1551152/000155115224000007/0001551152-24-000007-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1551152/000155115224000007/abbv-20240202.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001551152-24-000007
- JSON: https://secwatch.observer/filing/0001551152-24-000007.json
- Plain text: https://secwatch.observer/filing/0001551152-24-000007.txt

## Key facts
- Earnings Releases
  AbbVie Inc. reported the fourth quarter and full year ended December 31, 2023 results: revenue $14.301 billion, EPS $2.79. Guidance reaffirmed.
  - Period: the fourth quarter and full year ended December 31, 2023
  - Revenue: $14.301 billion
  - EPS: $2.79
  - Guidance: reaffirmed
  - Result: reported results
  source text: These Results Include an Unfavorable Impact of $0.15 Per Share Related to Fourth-Quarter 2023 Acquired IPR&D and Milestones Expense • Delivers Fourth-Quarter Net Revenues of $14.301 Billion, a Decrease of 5.4 Percent • Announced Definitive Transaction Agreements to Acquire ImmunoGen and Cerevel Therapeutics, Strengthening AbbVie’s Oncology and Neuroscience
  evidence_url: https://www.sec.gov/Archives/edgar/data/1551152/000155115224000007/0001551152-24-000007-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.